GoAI
Get started
Seer, Inc. logo

Seer, Inc.

SEER

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$2.03

+$0.01 · +0.50%

Aug 21, 4:00 PM ET

SEER company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

73

Undervalued

Momentum

53

Neutral

Sentiment

58

Mixed

Risk resilience

46

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Seer, Inc. is a life sciences firm specializing in developing and commercializing advanced technologies designed to unravel the complexities of the proteome. At the core of its offerings is the Proteograph Product Suite, an integrated platform comprising specialized consumables, automated instrumentation, and sophisticated software. This comprehensive solution empowers researchers to conduct advanced proteomic studies across various applications, including therapeutic and diagnostic investigations, as well as clinical trials. The company markets its products exclusively for research applications, serving academic institutions, diverse life sciences and research laboratories, and biopharmaceutical and biotechnology enterprises. Notably, these offerings are intended for non-diagnostic and non-clinical purposes. Seer has established collaborative agreements with entities such as Discovery Life Sciences, LLC, and the Salk Institute for Biological Studies. Originally incorporated in 2017 as Seer Biosciences, Inc., the company adopted its current name, Seer, Inc., in July 2018. Its headquarters are situated in Redwood City, California.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Omid C. Farokhzad
Listed since
Dec 4, 2020
Employees
124

Market position

Day range

Current $2.03

52-week range

Current $2.03

Open
$2.015
Previous close
$2.02
Volume
117.1K
0.13× average
Average volume
876.27K
Average daily volume
Market cap
111.61M USD
Beta
1.52
Market reference 1
50-day average
$1.9942
+1.80% above average
200-day average
$1.8993
+6.88% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
81.5M USD
P/E (TTM)
-1.66×
P/B (TTM)
0.5×
P/S (TTM)
8.06×
EV / EBITDA
-1.13×
Earnings yield
-70.01%
Free cash flow yield
-43.99%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
46.31%
Operating margin
-511.39%
Net margin
-490.71%
Return on equity
-28.38%
Return on assets
-24.86%
Return on invested capital
-27.56%

Financial health

Debt / equity
0.1×
Current ratio
12.84×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends167%-302%-770%-1238%Gross margin, FY2021: -5.85%Gross margin, FY2022: 2.61%Gross margin, FY2023: 9.54%Gross margin, FY2024: 48.99%Gross margin, FY2025: 49.67%Operating margin, FY2021: -1121.30%Operating margin, FY2022: -667.64%Operating margin, FY2023: -691.23%Operating margin, FY2024: -717.72%Operating margin, FY2025: -483.85%Net margin, FY2021: -1113.06%Net margin, FY2022: -633.07%Net margin, FY2023: -568.28%Net margin, FY2024: -620.91%Net margin, FY2025: -456.60%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 -5.85%. Gross margin FY2022 2.61%. Gross margin FY2023 9.54%. Gross margin FY2024 48.99%. Gross margin FY2025 49.67%. Operating margin FY2021 -1121.30%. Operating margin FY2022 -667.64%. Operating margin FY2023 -691.23%. Operating margin FY2024 -717.72%. Operating margin FY2025 -483.85%. Net margin FY2021 -1113.06%. Net margin FY2022 -633.07%. Net margin FY2023 -568.28%. Net margin FY2024 -620.91%. Net margin FY2025 -456.60%.

Income trends

Revenue

16.12M USD+15.57%

Operating income

−77.99M USD+22.09%

Net income

−73.6M USD+15.01%
Income trends across reported periods28.23M USD−20.2M USD−68.62M USD−117.05M USDRevenue, FY2021: 6.39M USDRevenue, FY2022: 14.69M USDRevenue, FY2023: 15.18M USDRevenue, FY2024: 13.95M USDRevenue, FY2025: 16.12M USDOperating income, FY2021: −71.7M USDOperating income, FY2022: −98.04M USDOperating income, FY2023: −104.94M USDOperating income, FY2024: −100.1M USDOperating income, FY2025: −77.99M USDNet income, FY2021: −71.17M USDNet income, FY2022: −92.97M USDNet income, FY2023: −86.28M USDNet income, FY2024: −86.6M USDNet income, FY2025: −73.6M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 6.39M USD. Revenue FY2022 14.69M USD. Revenue FY2023 15.18M USD. Revenue FY2024 13.95M USD. Revenue FY2025 16.12M USD. Operating income FY2021 −71.7M USD. Operating income FY2022 −98.04M USD. Operating income FY2023 −104.94M USD. Operating income FY2024 −100.1M USD. Operating income FY2025 −77.99M USD. Net income FY2021 −71.17M USD. Net income FY2022 −92.97M USD. Net income FY2023 −86.28M USD. Net income FY2024 −86.6M USD. Net income FY2025 −73.6M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue16.12M USD13.95M USD15.18M USD14.69M USD6.39M USD
Cost of goods sold8.11M USD7.12M USD13.73M USD14.3M USD6.77M USD
Gross profit8.01M USD6.83M USD1.45M USD384K USD−374K USD
Research and development43.87M USD50.59M USD47.44M USD45.8M USD29.12M USD
Selling, general, and administrative42.58M USD56.57M USD58.95M USD52.63M USD42.2M USD
Operating expenses86M USD106.93M USD106.39M USD98.43M USD71.32M USD
Interest income11.52M USD16.67M USD17.76M USD4.6M USD326K USD
Interest expense————22K USD
Depreciation and amortization6.1M USD6.18M USD5.58M USD5.9M USD3.56M USD
Operating income−77.99M USD−100.1M USD−104.94M USD−98.04M USD−71.7M USD
Net income−73.6M USD−86.6M USD−86.28M USD−92.97M USD−71.17M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
45%
5 beats, 5 misses, 1 met estimate
Average EPS surprise
+0.82%
11 comparable reports
Latest EPS result
-0.31
Estimate -0.27 · Miss by 14.81%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.22-0.29-0.36-0.43Q1 '25MissQ2 '25BeatQ3 '25BeatQ4 '25MetQ1 '26BeatQ2 '26MissQ3 '26MissQ4 '26Estimate
Q1 2025, reported Feb 27, 2025: actual -0.34, estimate -0.31, surprise -9.68%, Miss. Q2 2025, reported May 13, 2025: actual -0.34, estimate -0.37, surprise +8.11%, Beat. Q3 2025, reported Aug 6, 2025: actual -0.33, estimate -0.39, surprise +15.38%, Beat. Q4 2025, reported Nov 6, 2025: actual -0.32, estimate -0.32, surprise 0.00%, Met estimate. Q1 2026, reported Feb 26, 2026: actual -0.29, estimate -0.32, surprise +9.38%, Beat. Q2 2026, reported May 13, 2026: actual -0.3, estimate -0.295, surprise -1.69%, Miss. Q3 2026, reported Aug 11, 2026: actual -0.31, estimate -0.27, surprise -14.81%, Miss. Q4 2026, reported Nov 5, 2026: actual —, estimate -0.26, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates4.78M4.06M3.33M2.61MQ1 '25MissQ2 '25BeatQ3 '25BeatQ4 '25MissQ1 '26MissQ2 '26MissQ3 '26MissQ4 '26Estimate
Q1 2025, reported Feb 27, 2025: actual 3.95M USD, estimate 3.95M USD, surprise -0.03%, Miss. Q2 2025, reported May 13, 2025: actual 4.21M USD, estimate 4.05M USD, surprise +3.83%, Beat. Q3 2025, reported Aug 6, 2025: actual 4.05M USD, estimate 3.75M USD, surprise +8.03%, Beat. Q4 2025, reported Nov 6, 2025: actual 4.12M USD, estimate 4.6M USD, surprise -10.41%, Miss. Q1 2026, reported Feb 26, 2026: actual 4.2M USD, estimate 4.6M USD, surprise -8.67%, Miss. Q2 2026, reported May 13, 2026: actual 2.79M USD, estimate 3.6M USD, surprise -22.42%, Miss. Q3 2026, reported Aug 11, 2026: actual 3.1M USD, estimate 3.55M USD, surprise -12.62%, Miss. Q4 2026, reported Nov 5, 2026: actual —, estimate 4.15M USD, surprise —, Comparison unavailable.

SEER peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding SEER

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
2.71M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
883.43K
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Micro-Cap ETF logoiShares Micro-Cap ETFIWC
Market value
330.79K
Weight
0.02%
AUM
1.53B USD
Expense ratio
0.60%
Price / 1D
$198.39+1.10%
Avantis U.S. Small Cap Equity ETF logoAvantis U.S. Small Cap Equity ETFAVSC
Market value
124.29K
Weight
—
AUM
3.16B USD
Expense ratio
0.25%
Price / 1D
$73.84+0.70%
U.S. Micro Cap Portfolio ETF logoU.S. Micro Cap Portfolio ETFDFMC
Market value
76.41K
Weight
0.00%
AUM
8.06B USD
Expense ratio
0.43%
Price / 1D
$60.95+0.73%
Invesco RAFI US 1500 Small-Mid ETF logoInvesco RAFI US 1500 Small-Mid ETFPRFZ
Market value
47.82K
Weight
0.00%
AUM
2.87B USD
Expense ratio
0.34%
Price / 1D
$55.89+0.87%
Dimensional - US Sustainability Core 1 ETF logoDimensional - US Sustainability Core 1 ETFDFSU
Market value
22.93K
Weight
0.00%
AUM
2.35B USD
Expense ratio
0.15%
Price / 1D
$48.20+0.52%
Avantis U.S. Equity ETF logoAvantis U.S. Equity ETFAVUS
Market value
14.09K
Weight
—
AUM
14.45B USD
Expense ratio
0.15%
Price / 1D
$130.59+0.52%

Continue in GoAI

Research SEER

research.disclaimer